BioSpace News Archive

Drug Development

KalVista’s Eye Drug for Diabetic Macular Edema Flunks Mid-Stage Trial

The primary efficacy endpoint was change in best corrected visual acuity (BCVA) at 16 weeks compared to sham (placebo) treatment.

December 9, 2019
·
2 min read
·
Mark Terry
Biotech Beach

Takeaways from ASHG 2019 in Houston: Users of Bionano’s Saphyr System Presented Validation Results for FSHD, Repeat Expansion Disorders and Digital Cytogenetics Among a Growing List of Applications of Saphyr in Human Genetics and Cancer Research

Saphyr provides a platform that streamlines traditional workflows and provides a path to solving previously intractable scientific questions connected to the mechanisms of disease

December 9, 2019
·
8 min read
Business

Clinician scientist studying multiple myeloma wins the first Proteona Oncology Challenge

Proteona Pte. Ltd. has announced the results of the firstProteona Oncology Challenge, co-sponsored by NovogeneAIT.

December 9, 2019
·
3 min read
Global Food Security Index 2019 Highlights the Growing Threat of Climate Change as Food Security Decreases Worldwide

Exposure to environmental factors such as land degradation and volatile climate patterns diminishing food security on a global scale

December 9, 2019
·
5 min read
Peregrine Ventures Raises $115 Million for its Fourth Fund Bringing Total Managed Funds and Co-Invest Capital to $400 Million

Peregrine Ventures, a leading Israeli med-tech venture capital fund, just closed its fourth fund, Peregrine 4, raising $115 million.

December 9, 2019
·
3 min read
Deals

Aqilion sells shareholdings in portfolio company Glactone Pharma

AQILION AB is selling its entire stake in the portfolio company Glactone Pharma AB to Daniel Lifveredson Invest AB.

December 9, 2019
·
2 min read
With Strong PFS Data in Hand, AstraZeneca’s Calquence Sets Sights on Imbruvica

AstraZeneca released new data that shows Calquence as a monotherapy and combined with Roche’s anti-CD20 drug Gazyva significantly improved progression-free survival in previously untreated CLL.

December 9, 2019
·
3 min read
·
Alex Keown
Deals

Epidarex Exeed Founded by Epidarex Capital to Advance Early Stage, Highly Innovative Life Science Assets

Epidarex’s therapeutic discovery engine will identify innovative early stage assets, providing hands-on scientific support and funding to drive drug discovery projects

December 9, 2019
·
1 min read
Business

Healx Joins Forces with Boehringer Ingelheim to Discover New Treatment Approaches for Rare Neurological Diseases

The collaboration will leverage Healx’s AI technologies and rare disease expertise to advance Boehringer Ingelheim’s drug discovery programme

December 9, 2019
·
3 min read
Drug Development

Algernon Pharmaceuticals Selects NP-120 (Ifenprodil) for its Lead Phase 2 Trial for Idiopathic Pulmonary Fibrosis and Chronic Cough

Algernon Pharmaceuticals Inc., a clinical stage pharmaceutical development company, is pleased to announce that it plans to conduct its first phase 2 clinical trial of its repurposed drug NP-120 for patients with idiopathic pulmonary fibrosis and chronic cough.

December 9, 2019
·
5 min read